LIP
CBIO

Lighthouse Investment Partners’s Crescent Biopharma CBIO Stock Holding History

Lighthouse Investment Partners’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-25,000
Closed -$459K – 823
2026
Q1 		$459K Buy
+25,000
New +$287K 0.02% 532

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Lighthouse Investment Partners's CBIO Position: Q2 2026 in Review

Lighthouse Investment Partners sold out of Crescent Biopharma (CBIO) in Q2 2026, closing a stake of 25,000 shares — an estimated $459K sold.

Lighthouse Investment Partners first reported a position in CBIO in Q1 2026 and held it in 1 quarter. The position peaked at $459K in Q1 2026. 82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • Lighthouse Investment Partners reported no remaining Crescent Biopharma position as of Q2 2026 after selling out during the quarter.
  • Lighthouse Investment Partners sold 25,000 Crescent Biopharma shares in Q2 2026, an estimated $459K.
  • Lighthouse Investment Partners first reported a position in Crescent Biopharma in Q1 2026 and held it in 1 quarter.
  • Lighthouse Investment Partners's Crescent Biopharma position peaked at $459K in Q1 2026.
  • 82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Lighthouse Investment Partners's 13F filing for Q2 2026, filed 14 Aug 2026.